Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins

Progress in Neurobiology

Volumn 97, Issue 2, 2012, Pages 190-204

  Butler, David C ^a   McLear, Julie A ^c   Messer, Anne ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UTICA COLLEGE   (United States)

Author keywords

Huntington's disease; Intrabody; Nanobody; Polyglutamine; Single chain Fv

Indexed keywords

ANTIBODY; CELL PROTEIN; CHAPERONE; GLUTATHIONE TRANSFERASE; HUNTINGTIN; HUNTINGTIN ANTIBODY; HYBRID PROTEIN; INTRABODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EM48; NANOBODY; POLYGLUTAMINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ACETYLATION; AMINO TERMINAL SEQUENCE; ANTIBODY AFFINITY; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; AUTOPHAGY; BASAL GANGLION; BINDING SITE; BLOOD BRAIN BARRIER; CAG REPEAT; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; CHIMERA; DROSOPHILA MELANOGASTER; DRUG SAFETY; DRUG TARGETING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; EXON; GENE DELIVERY SYSTEM; GENE TARGETING; HUMAN; HUNTINGTON CHOREA; HYDROPHILICITY; INFECTION; MOTOR DYSFUNCTION; NEOPLASM; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REVIEW; SUBSTANTIA NIGRA; SUMOYLATION; THALAMUS; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UBIQUITINATION;

ANIMALS; ANTIBODIES; HUMANS; HUNTINGTON DISEASE; MICE; MUTANT PROTEINS; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84860692601     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.11.004     Document Type: Review

References (167)

1. Agashe V.R., Hartl F.U. Roles of molecular chaperones in cytoplasmic protein folding. Semin. Cell Dev. Biol. 2000, 11:15-25.
2. Agrawal N., Pallos J., Slepko N., Apostol B.L., Bodai L., Chang L.W., Chiang A.S., Thompson L.M., Marsh J.L. Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3777-3781.
3. Aiken C.T., Steffan J.S., Guerrero C.M., Khashwji H., Lukacsovich T., Simmons D., Purcell J.M., Menhaji K., Zhu Y.Z., Green K., Laferla F., Huang L., Thompson L.M., Marsh J.L. Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J. Biol. Chem. 2009, 284:29427-29436.
4. Aires da Silva F., Santa-Marta M., Freitas-Vieira A., Mascarenhas P., Barahona I., Moniz-Pereira J., Gabuzda D., Goncalves J. Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity. J. Mol. Biol. 2004, 340:525-542.
5. Allay J.A., Sleep S., Long S., Tillman D.M., Clark R., Carney G., Fagone P., McIntosh J.H., Nienhuis A.W., Davidoff A.M., Nathwani A.C., Gray J.T. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum. Gene Ther. 2011, 22:595-604.
6. Atwal J.K., Chen Y., Chiu C., Mortensen D.L., Meilandt W.J., Liu Y., Heise C.E., Hoyte K., Luk W., Lu Y., Peng K., Wu P., Rouge L., Zhang Y., Lazarus R.A., Scearce-Levie K., Wang W., Wu Y., Tessier-Lavigne M., Watts R.J. A therapeutic antibody targeting BACE1 inhibits amyloid-beta production in vivo. Sci Transl Med. 2011, 3:84ra43.
7. Atwal R.S., Xia J., Pinchev D., Taylor J., Epand R.M., Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 2007, 16:2600-2615.
8. Auerbach W., Hurlbert M.S., Hilditch-Maguire P., Wadghiri Y.Z., Wheeler V.C., Cohen S.I., Joyner A.L., MacDonald M.E., Turnbull D.H. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum. Mol. Genet. 2001, 10:2515-2523.
9. Auf der Maur A., Escher D., Barberis A. Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Lett. 2001, 508:407-412.
10. Barkhordarian H., Emadi S., Schulz P., Sierks M.R. Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng. Des. Sel. 2006, 19:497-502.
11. Bateman J.R., Lee A.M., Wu C.T. Site-specific transformation of Drosophila via phiC31 integrase-mediated cassette exchange. Genetics 2006, 173:769-777.
12. Bauer P.O., Goswami A., Wong H.K., Okuno M., Kurosawa M., Yamada M., Miyazaki H., Matsumoto G., Kino Y., Nagai Y., Nukina N. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat. Biotechnol. 2010, 28:256-263.
13. Becher M.W., Kotzuk J.A., Sharp A.H., Davies S.W., Bates G.P., Price D.L., Ross C.A. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol. Dis. 1998, 4:387-397.
14. Becher M.W., Ross C.A. Intranuclear neuronal inclusions in DRPLA. Mov. Disord. 1998, 13:852-853.
15. Bejarano E., Cuervo A.M. Chaperone-mediated autophagy. Proc. Am. Thorac. Soc. 2010, 7:29-39.
16. Bischof J., Maeda R.K., Hediger M., Karch F., Basler K. An optimized transgenesis system for Drosophila using germ-line-specific phiC31 integrases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3312-3317.
17. Boder E.T., Wittrup K.D. Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods Enzymol. 2000, 328:430-444.
18. Bortvedt S.F., McLear J.A., Messer A., Ahern-Rindell A.J., Wolfgang W.J. Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease. Neurobiol. Dis. 2010, 40:130-134.
19. Boudreau R.L., Rodriguez-Lebron E., Davidson B.L. RNAi medicine for the brain: progresses and challenges. Hum. Mol. Genet. 2011, 20:R21-R27.
20. Bowers W.J., Breakefield X.O., Sena-Esteves M. Genetic therapy for the nervous system. Hum. Mol. Genet. 2011, 20:R28-R41.
21. Brand A.H., Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118:401-415.
22. Butler, D. C. and Messer, A. 2011. Bifunctional anti-Huntingtin Proteasome-Directed Intrabodies Mediate Efficient Degradation of Mutant Huntingtin Exon 1 Protein Fragments. PLoS ONE, in Press.
23. Cardinale A., Biocca S. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases. Trends Mol. Med. 2008, 14:373-380.
24. Carlson J.R. A new means of inducibly inactivating a cellular protein. Mol. Cell. Biol. 1988, 8:2638-2646.
25. Caviston J.P., Holzbaur E.L. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 2009, 19:147-155.
26. Cearley C.N., Vandenberghe L.H., Parente M.K., Carnish E.R., Wilson J.M., Wolfe J.H. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol. Ther. 2008, 16:1710-1718.
27. Cepeda C., Wu N., Andre V.M., Cummings D.M., Levine M.S. The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 2007, 81:253-271.
28. Chartier A., Raz V., Sterrenburg E., Verrips C.T., van der Maarel S.M., Simonelig M. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo. Hum. Mol. Genet. 2009, 18:1849-1859.
29. Colby D.W., Chu Y., Cassady J.P., Duennwald M., Zazulak H., Webster J.M., Messer A., Lindquist S., Ingram V.M., Wittrup K.D. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17616-17621.
30. Colby D.W., Garg P., Holden T., Chao G., Webster J.M., Messer A., Ingram V.M., Wittrup K.D. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display. J. Mol. Biol. 2004, 342:901-912.
31. Colby D.W., Kellogg B.A., Graff C.P., Yeung Y.A., Swers J.S., Wittrup K.D. Engineering antibody affinity by yeast surface display. Methods Enzymol. 2004, 388:348-358.
32. Cornett J., Cao F., Wang C.E., Ross C.A., Bates G.P., Li S.H., Li X.J. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat. Genet. 2005, 37:198-204.
33. Crook Z.R., Housman D. Huntington's disease: can mice lead the way to treatment?. Neuron 2011, 69:423-435.
34. Dai Y., Dudek N.L., Li Q., Fowler S.C., Muma N.A. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease. J. Neurosci. 2009, 29:11550-11559.
35. Daneman R., Barres B.A. The blood-brain barrier-lessons from moody flies. Cell 2005, 123:9-12.
36. Davies J., Riechmann L. 'Camelising' human antibody fragments: NMR studies on VH domains. FEBS Lett. 1994, 339:285-290.
37. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., Matson W.R., Cooper A.J., Ratan R.R., Beal M.F., Hersch S.M., Ferrante R.J. Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci. 2002, 22:8942-8950.
38. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
39. DiFiglia M., Sena-Esteves M., Chase K., Sapp E., Pfister E., Sass M., Yoder J., Reeves P., Pandey R.K., Rajeev K.G., Manoharan M., Sah D.W., Zamore P.D., Aronin N. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17204-17209.
40. Doorbar J., Griffin H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin. Biol. Ther. 2007, 7:677-689.
41. Duffy J.B. GAL4 system in Drosophila: a fly geneticist's Swiss army knife. Genesis 2002, 34:1-15.
42. Duyao M.P., Auerbach A.B., Ryan A., Persichetti F., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.F., Joyner A.L., et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
43. Emadi S., Barkhordarian H., Wang M.S., Schulz P., Sierks M.R. Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J. Mol. Biol. 2007, 368:1132-1144.
44. Emadi S., Liu R., Yuan B., Schulz P., McAllister C., Lyubchenko Y., Messer A., Sierks M.R. Inhibiting aggregation of a-synuclein with human single chain antibody fragments. Biochemistry 2004, 43:2871-2878.
45. Ewert K., Slack N.L., Ahmad A., Evans H.M., Lin A.J., Samuel C.E., Safinya C.R. Cationic lipid-DNA complexes for gene therapy: understanding the relationship between complex structure and gene delivery pathways at the molecular level. Curr. Med. Chem. 2004, 11:133-149.
46. Feldhaus M.J., Siegel R.W., Opresko L.K., Coleman J.R., Feldhaus J.M., Yeung Y.A., Cochran J.R., Heinzelman P., Colby D., Swers J., Graff C., Wiley H.S., Wittrup K.D. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol. 2003, 21:163-170.
47. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
48. Ghoda L., van Daalen Wetters T., Macrae M., Ascherman D., Coffino P. Prevention of rapid intracellular degradation of ODC by a carboxyl-terminal truncation. Science 1989, 243:1493-1495.
49. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 2008, 28:6182-6195.
50. Gray S.J., Matagne V., Bachaboina L., Yadav S., Ojeda S.R., Samulski R.J. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 2011, 19:1058-1069.
51. Groot A.J., Gort E.H., van der Wall E., van Diest P.J., Vooijs M. Conditional inactivation of HIF-1 using intrabodies. Cell Oncol. 2008, 30:397-409.
52. Gu X., Greiner E.R., Mishra R., Kodali R., Osmand A., Finkbeiner S., Steffan J.S., Thompson L.M., Wetzel R., Yang X.W. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 2009, 64:828-840.
53. Gutekunst C.A., Li S.H., Yi H., Mulroy J.S., Kuemmerle S., Jones R., Rye D., Ferrante R.J., Hersch S.M., Li X.J. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J. Neurosci. 1999, 19:2522-2534.
54. Habicht G., Haupt C., Friedrich R.P., Hortschansky P., Sachse C., Meinhardt J., Wieligmann K., Gellermann G.P., Brodhun M., Gotz J., Halbhuber K.J., Rocken C., Horn U., Fandrich M. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:19232-19237.
55. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77:13-22.
56. Hathorn T., Snyder-Keller A., Messer A. Nicotinamide improves motor deficits and upregulates PGC-1alpha and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol. Dis. 2011, 41:43-50.
57. Hirth F. Drosophila melanogaster in the study of human neurodegeneration. CNS Neurol. Disord. Drug Targets 2010, 9:504-523.
58. Hockly E., Richon V.M., Woodman B., Smith D.L., Zhou X., Rosa E., Sathasivam K., Ghazi-Noori S., Mahal A., Lowden P.A., Steffan J.S., Marsh J.L., Thompson L.M., Lewis C.M., Marks P.A., Bates G.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2041-2046.
59. Holmberg M., Duyckaerts C., Durr A., Cancel G., Gourfinkel-An I., Damier P., Faucheux B., Trottier Y., Hirsch E.C., Agid Y., Brice A. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 1998, 7:913-918.
60. Holt L.J., Herring C., Jespers L.S., Woolven B.P., Tomlinson I.M. Domain antibodies: proteins for therapy. Trends Biotechnol. 2003, 21:484-490.
61. Horodyski F.M., Ewer J., Riddiford L.M., Truman J.W. Isolation, characterization and expression of the eclosion hormone gene of Drosophila melanogaster. Eur. J. Biochem. 1993, 215:221-228.
62. Imarisio S., Carmichael J., Korolchuk V., Chen C.W., Saiki S., Rose C., Krishna G., Davies J.E., Ttofi E., Underwood B.R., Rubinsztein D.C. Huntington's disease: from pathology and genetics to potential therapies. Biochem. J. 2008, 412:191-209.
63. Jana N.R., Dikshit P., Goswami A., Kotliarova S., Murata S., Tanaka K., Nukina N. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 2005, 280:11635-11640.
64. Kahlem P., Terre C., Green H., Djian P. Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14580-14585.
65. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
66. Khoshnan A., Ko J., Patterson P.H. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1002-1007.
67. Klein R.L., Dayton R.D., Tatom J.B., Henderson K.M., Henning P.P. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol. Ther. 2008, 16:89-96.
68. Ko J., Ou S., Patterson P.H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 2001, 56:319-329.
69. Kvam E., Nannenga B.L., Wang M.S., Jia Z., Sierks M.R., Messer A. Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS ONE 2009, 4:e5727.
70. Kvam E., Sierks M.R., Shoemaker C.B., Messer A. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Eng. Des. Sel. 2010, 23:489-498.
71. La Spada A.R., Taylor J.P. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nat. Rev. Genet. 2010, 11:247-258.
72. Lecerf J.M., Shirley T.L., Zhu Q., Kazantsev A., Amersdorfer P., Housman D.E., Messer A., Huston J.S. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:4764-4769.
73. Leclerc G.M., Boockfor F.R., Faught W.J., Frawley L.S. Development of a destabilized firefly luciferase enzyme for measurement of gene expression. Biotechniques 2000, 29:590-591. 594-596, 598 passim.
74. Lee T., Luo L. Mosaic analysis with a repressible cell marker (MARCM) for Drosophila neural development. Trends Neurosci. 2001, 24:251-254.
75. Lentz T.B., Gray S.J., Samulski R.J. Viral vectors for gene delivery to the central nervous system. Neurobiol. Dis. 2011, 10.1016/j.nbd.2011.09.014.
76. Lewis E.B. A gene complex controlling segmentation in Drosophila. Nature 1978, 276:565-570.
77. Li P., Huey-Tubman K.E., Gao T., Li X., West A.P., Bennett M.J., Bjorkman P.J. The structure of a polyQ-anti-polyQ complex reveals binding according to a linear lattice model. Nat. Struct. Mol. Biol. 2007, 14:381-387.
78. Li W., Asokan A., Wu Z., Van Dyke T., DiPrimio N., Johnson J.S., Govindaswamy L., Agbandje-McKenna M., Leichtle S., Redmond D.E., McCown T.J., Petermann K.B., Sharpless N.E., Samulski R.J. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 2008, 16:1252-1260.
79. Li X., Wang C.E., Huang S., Xu X., Li X.J., Li H., Li S. Inhibiting the ubiquitin-proteasome system leads to preferential accumulation of toxic N-terminal mutant huntingtin fragments. Hum. Mol. Genet. 2010, 19:2445-2455.
80. Li X., Zhao X., Fang Y., Jiang X., Duong T., Fan C., Huang C.C., Kain S.R. Generation of destabilized green fluorescent protein as a transcription reporter. J. Biol. Chem. 1998, 273:34970-34975.
81. Li X.J., Li H., Li S. Clearance of mutant huntingtin. Autophagy 2010, 6.
82. Li X.J., Li S. Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 2011, 43:4-8.
83. Lo A.S., Zhu Q., Marasco W.A. Intracellular antibodies (intrabodies) and their therapeutic potential. Handb. Exp. Pharmacol. 2008, 343-373.
84. Lobato M.N., Rabbitts T.H. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol. Med. 2003, 9:390-396.
85. Lunnon K., Teeling J.L., Tutt A.L., Cragg M.S., Glennie M.J., Perry V.H. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J. Immunol. 2011, 186:7215-7224.
86. Lynch S.M., Zhou C., Messer A. An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol. 2008, 377:136-147.
87. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
88. Marasco W.A., Chen S., Richardson J.H., Ramstedt U., Jones S.D. Intracellular antibodies against HIV-1 envelope protein for AIDS gene therapy. Hum. Gene Ther. 1998, 9:1627-1642.
89. Martineau P., Jones P., Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J. Mol. Biol. 1998, 280:117-127.
90. McCarty D.M., Monahan P.E., Samulski R.J. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001, 8:1248-1254.
91. McLear J.A., Lebrecht D., Messer A., Wolfgang W.J. Combinational approach of intrabody with enhanced Hsp70 expression addresses multiple pathologies in a fly model of Huntington's disease. FASEB J. 2008, 22:2003-2011.
92. Melchionna T., Cattaneo A. A protein silencing switch by ligand-induced proteasome-targeting intrabodies. J. Mol. Biol. 2007, 374:641-654.
93. Messer A., Lynch S.M., Butler D.C. Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opin. Biol. Ther. 2009, 9:1189-1197.
94. Messer A., McLear J. The therapeutic potential of intrabodies in neurologic disorders: focus on huntington and Parkinson diseases. BioDrugs 2006, 20:327-333.
95. Miller T.W., Messer A. Gene therapy for CNS diseases using intrabodies. Gene Therapy of the Central Nervous System: From Bench to Bedside 2006, 133-150. Academic Press, Amsterdam; Boston. M.G. Kaplitt, M.J. During (Eds.).
96. Miller T.W., Shirley T.L., Wolfgang W.J., Kang X., Messer A. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol. Ther. 2003, 7:572-579.
97. Miller T.W., Zhou C., Gines S., MacDonald M.E., Mazarakis N.D., Bates G.P., Huston J.S., Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiol. Dis. 2005, 19:47-56.
98. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
99. Mukhtar M.M., Li S., Li W., Wan T., Mu Y., Wei W., Kang L., Rasool S.T., Xiao Y., Zhu Y., Wu J. Single-chain intracellular antibodies inhibit influenza virus replication by disrupting interaction of proteins involved in viral replication and transcription. Int. J. Biochem. Cell Biol. 2009, 41:554-560.
100. Murphy R.C., Messer A. A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease. Brain Res. Mol. Brain Res. 2004, 121:141-145.
101. Muyldermans S., Baral T.N., Retamozzo V.C., De Baetselier P., De Genst E., Kinne J., Leonhardt H., Magez S., Nguyen V.K., Revets H., Rothbauer U., Stijlemans B., Tillib S., Wernery U., Wyns L., Hassanzadeh-Ghassabeh G., Saerens D. Camelid immunoglobulins and nanobody technology. Vet. Immunol. Immunopathol. 2009, 128:178-183.
102. Nagai Y., Fujikake N., Ohno K., Higashiyama H., Popiel H.A., Rahadian J., Yamaguchi M., Strittmatter W.J., Burke J.R., Toda T. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum. Mol. Genet. 2003, 12:1253-1259.
103. Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 2007, 14:332-340.
104. Nagai Y., Tucker T., Ren H., Kenan D.J., Henderson B.S., Keene J.D., Strittmatter W.J., Burke J.R. Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J. Biol. Chem. 2000, 275:10437-10442.
105. Nusslein-Volhard C., Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287:795-801.
106. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1485-1490.
107. Omi K., Hachiya N.S., Tanaka M., Tokunaga K., Kaneko K. 14-3-3zeta is indispensable for aggregate formation of polyglutamine-expanded huntingtin protein. Neurosci. Lett. 2008, 431:45-50.
108. Orlandi R., Gussow D.H., Jones P.T., Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:3833-3837.
109. Paulson H.L., Das S.S., Crino P.B., Perez M.K., Patel S.C., Gotsdiner D., Fischbeck K.H., Pittman R.N. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 1997, 41:453-462.
110. Paz K., Brennan L.A., Iacolina M., Doody J., Hadari Y.R., Zhu Z. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol. Cancer Ther. 2005, 4:1801-1809.
111. Perchiacca J.M., Bhattacharya M., Tessier P.M. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins 2011, 79:2637-2647.
112. Perez-Martinez D., Tanaka T., Rabbitts T.H. Intracellular antibodies and cancer: new technologies offer therapeutic opportunities. Bioessays 2010, 32:589-598.
113. Persic L., Righi M., Roberts A., Hoogenboom H.R., Cattaneo A., Bradbury A. Targeting vectors for intracellular immunisation. Gene 1997, 187:1-8.
114. Popiel H.A., Nagai Y., Fujikake N., Toda T. Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo. Mol. Ther. 2007, 15:303-309.
115. Popiel H.A., Nagai Y., Fujikake N., Toda T. Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice. Neurosci. Lett. 2009, 449:87-92.
116. Qin Z.H., Wang Y., Sapp E., Cuiffo B., Wanker E., Hayden M.R., Kegel K.B., Aronin N., DiFiglia M. Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J. Neurosci. 2004, 24:269-281.
117. Ravikumar B., Duden R., Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 2002, 11:1107-1117.
118. Ren H., Nagai Y., Tucker T., Strittmatter W.J., Burke J.R. Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death. Biochem. Biophys. Res. Commun. 2001, 288:703-710.
119. Rockabrand E., Slepko N., Pantalone A., Nukala V.N., Kazantsev A., Marsh J.L., Sullivan P.G., Steffan J.S., Sensi S.L., Thompson L.M. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 2007, 16:61-77.
120. Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 2005, 12:618-633.
121. Roovers R.C., van Dongen G.A., van Bergen en Henegouwen P.M. Nanobodies in therapeutic applications. Curr. Opin. Mol. Ther. 2007, 9:327-335.
122. Rose C., Menzies F.M., Renna M., Acevedo-Arozena A., Corrochano S., Sadiq O., Brown S.D., Rubinsztein D.C. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum. Mol. Genet. 2010, 19:2144-2153.
123. Saerens D., Pellis M., Loris R., Pardon E., Dumoulin M., Matagne A., Wyns L., Muyldermans S., Conrath K. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 2005, 352:597-607.
124. Sah D.W., Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J. Clin. Invest. 2011, 121:500-507.
125. Sapp E., Schwarz C., Chase K., Bhide P.G., Young A.B., Penney J., Vonsattel J.P., Aronin N., DiFiglia M. Huntingtin localization in brains of normal and Huntington's disease patients. Ann. Neurol. 1997, 42:604-612.
126. Sarkar S., Rubinsztein D.C. Huntington's disease: degradation of mutant huntingtin by autophagy. FEBS J. 2008, 275:4263-4270.
127. Schiefner A., Chatwell L., Korner J., Neumaier I., Colby D.W., Volkmer R., Wittrup K.D., Skerra A. A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition. J. Mol. Biol. 2011, 10.1016/j.jmb.2011.09.034.
128. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 1999, 8:397-407.
129. Seabrooke S., Stewart B.A. Synaptic transmission and plasticity are modulated by nonmuscle myosin II at the neuromuscular junction of Drosophila. J. Neurophysiol. 2011, 105:1966-1976.
130. Shlyakhtenko L.S., Yuan B., Emadi S., Lyubchenko Y.L., Sierks M.R. Single-molecule selection and recovery of structure-specific antibodies using atomic force microscopy. Nanomedicine 2007, 3:192-197.
131. Shuntao W., Jiannan F., Jianwei G., Leiming G., Yan L., Yingxun S., Weisong Q., Meiru H., Gencheng H., Beifen S. A novel designed single domain antibody on 3-D structure of ricin A chain remarkably blocked ricin-induced cytotoxicity. Mol. Immunol. 2006, 43:1912-1919.
132. Sibler A.P., Courtete J., Muller C.D., Zeder-Lutz G., Weiss E. Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells. FEBS J. 2005, 272:2878-2891.
133. Sieradzan K.A., Mann D.M. The selective vulnerability of nerve cells in Huntington's disease. Neuropathol. Appl. Neurobiol. 2001, 27:1-21.
134. Skinner P.J., Koshy B.T., Cummings C.J., Klement I.A., Helin K., Servadio A., Zoghbi H.Y., Orr H.T. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997, 389:971-974.
135. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
136. Snyder-Keller A., McLear J.A., Hathorn T., Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J. Neuropathol. Exp. Neurol. 2010, 69:1078-1085.
137. Solomon B., Frenkel D. Immunotherapy for Alzheimer's disease. Neuropharmacology 2010, 59:303-309.
138. Southwell A.L., Bugg C.W., Kaltenbach L.S., Dunn D., Butland S., Weiss A., Paganetti P., Lo D.C., Patterson P.H. Perturbation with intrabodies reveals that calpain cleavage is required for degradation of huntingtin exon 1. PLoS ONE 2011, 6:e16676.
139. Southwell A.L., Khoshnan A., Dunn D.E., Bugg C.W., Lo D.C., Patterson P.H. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J. Neurosci. 2008, 28:9013-9020.
140. Southwell A.L., Ko J., Patterson P.H. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 2009, 29:13589-13602.
141. Southwell A.L., Patterson P.H. Gene therapy in mouse models of huntington disease. Neuroscientist 2011, 17:153-162.
142. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., Pandolfi P.P., Thompson L.M., Marsh J.L. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
143. Steffan J.S., Bodai L., Pallos J., Poelman M., McCampbell A., Apostol B.L., Kazantsev A., Schmidt E., Zhu Y.Z., Greenwald M., Kurokawa R., Housman D.E., Jackson G.R., Marsh J.L., Thompson L.M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001, 413:739-743.
144. Steinberger P., Andris-Widhopf J., Buhler B., Torbett B.E., Barbas C.F. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:805-810.
145. Sturtevant A.H. A third group of linked genes in drosophila ampelophila. Science 1913, 37:990-992.
146. Sudol K.L., Mastrangelo M.A., Narrow W.C., Frazer M.E., Levites Y.R., Golde T.E., Federoff H.J., Bowers W.J. Generating differentially targeted amyloid-beta specific intrabodies as a passive vaccination strategy for Alzheimer's disease. Mol. Ther. 2009, 17:2031-2040.
147. Tanaka T., Sewell H., Waters S., Phillips S.E., Rabbitts T.H. Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain. J. Biol. Chem. 2011, 286:3707-3716.
148. Tanaka T., Williams R.L., Rabbitts T.H. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J. 2007, 26:3250-3259.
149. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983. The Huntington's Disease Collaborative Research Group.
150. Varma H., Lo D.C., Stockwell B.R. High-Throughput and High-Content Screening for Huntington's Disease Therapeutics 2011.
151. Venken K.J., He Y., Hoskins R.A., Bellen H.J. P[acman]: a BAC transgenic platform for targeted insertion of large DNA fragments in D. melanogaster. Science 2006, 314:1747-1751.
152. Verhoef L.G., Lindsten K., Masucci M.G., Dantuma N.P. Aggregate formation inhibits proteasomal degradation of polyglutamine proteins. Hum. Mol. Genet. 2002, 11:2689-2700.
153. Visintin M., Tse E., Axelson H., Rabbitts T.H., Cattaneo A. Selection of antibodies for intracellular function using a two-hybrid in vivo system. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:11723-11728.
154. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44:559-577.
155. Wang C.E., Zhou H., McGuire J.R., Cerullo V., Lee B., Li S.H., Li X.J. Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J. Cell Biol. 2008, 181:803-816.
156. Wexler N.S., Lorimer J., Porter J., Gomez F., Moskowitz C., Shackell E., Marder K., Penchaszadeh G., Roberts S.A., Gayan J., Brocklebank D., Cherny S.S., Cardon L.R., Gray J., Dlouhy S.R., Wiktorski S., Hodes M.E., Conneally P.M., Penney J.B., Gusella J., Cha J.H., Irizarry M., Rosas D., Hersch S., Hollingsworth Z., MacDonald M., Young A.B., Andresen J.M., Housman D.E., De Young M.M., Bonilla E., Stillings T., Negrette A., Snodgrass S.R., Martinez-Jaurrieta M.D., Ramos-Arroyo M.A., Bickham J., Ramos J.S., Marshall F., Shoulson I., Rey G.J., Feigin A., Arnheim N., Acevedo-Cruz A., Acosta L., Alvir J., Fischbeck K., Thompson L.M., Young A., Dure L., O'Brien C.J., Paulsen J., Brickman A., Krch D., Peery S., Hogarth P., Higgins D.S., Landwehrmeyer B. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3498-3503.
157. Weyhersmuller A., Hallermann S., Wagner N., Eilers J. Rapid active zone remodeling during synaptic plasticity. J. Neurosci. 2011, 31:6041-6052.
158. Wilhelm B.G., Groemer T.W., Rizzoli S.O. The same synaptic vesicles drive active and spontaneous release. Nat. Neurosci. 2010, 13:1454-1456.
159. Wisniewski T., Sigurdsson E.M. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim. Biophys. Acta 2010, 1802:847-859.
160. Wolfgang W.J., Miller T.W., Webster J.M., Huston J.S., Thompson L.M., Marsh J.L., Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11563-11568.
161. Young A.B. Huntingtin in health and disease. J. Clin. Invest. 2003, 111:299-302.
162. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., Dennis M.S. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3:84ra44.
163. Zhan X., Ander B.P., Liao I.H., Hansen J.E., Kim C., Clements D., Weisbart R.H., Nishimura R.N., Sharp F.R. Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke 2010, 41:538-543.
164. Zhou C., Emadi S., Sierks M.R., Messer A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 2004, 10:1023-1031.
165. Zhou C., Przedborski S. Intrabody and Parkinson's disease. Biochim. Biophys. Acta 2008, 1792:634-642.
166. Zhou P., Bogacki R., McReynolds L., Howley P.M. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol. Cell 2000, 6:751-756.
167. Zuccato C., Valenza M., Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.